SOW
VRDN icon

State of Wyoming’s Viridian Therapeutics VRDN Stock Holding History

State of Wyoming’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7K Sell
2,327
-2,437
-51% -$39.3K ﹤0.01% 1716
2026
Q1 		$93.2K Buy
+4,764
New +$141K 0.01% 1296

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

State of Wyoming's VRDN Position: Q2 2026 in Review

State of Wyoming reduced its Viridian Therapeutics (VRDN) stake by 51% in Q2 2026, selling an estimated $39.3K and leaving 2,327 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

State of Wyoming first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $93.2K in Q1 2026. 103 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • State of Wyoming held 2,327 shares of Viridian Therapeutics worth $42.7K as of Q2 2026.
  • State of Wyoming sold 2,437 Viridian Therapeutics shares in Q2 2026, an estimated $39.3K.
  • Viridian Therapeutics made up ﹤0.01% of State of Wyoming's portfolio in Q2 2026, its #1716 holding.
  • State of Wyoming first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • State of Wyoming's Viridian Therapeutics position peaked at $93.2K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.